X

Drug Profile

AM 1030

Alternative Names: AM1030

Latest Information Update: 01 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AnaMar AB
Developer AnaMar AB; Labcorp Drug Development
Class Anti-inflammatories; Skin disorder therapies; Small molecules
Mechanism of Action Serotonin 2B receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Atopic dermatitis

Most Recent Events

05 Sep 2017 Discontinued - Phase-I/II for Atopic dermatitis in United Kingdom (Topical) (AnaMar AB pipeline, September 2017)
11 Aug 2015 AnaMar AB completes a phase I/II trial for Atopic dermatitis in the United Kingdom
03 Feb 2015 AM 1030 is available for licensing as of 03 Feb 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com